In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Sumitomo Pharma Co., Ltd.

https://www.sumitomo-pharma.com/

Latest From Sumitomo Pharma Co., Ltd.

Poxel Looks To More Twymeeg Partnerships In Asia To Pay Off Debt

Bookmark
  • News
By Ayisha Sharma

The French firm’s antidiabetic drug has enjoyed some traction in the Japanese market following the end of launch year restrictions, raising hopes that other Asian partnerships could help improve its financial position.

Sales & Earnings Deals

Finance Watch: Royalty Deals Pick Up As Alternative Financings Find Appeal

Bookmark
  • Analysis
By Mandy Jackson

Public Company Edition: Seven companies revealed $2.1bn worth of royalty financings in the first quarter of 2023 and the deals keep coming in Q2, with uniQure monetizing Hemgenix royalties for up to $400m. Also, Legend grossed $350m in a follow-on offering and Athenex is liquidating via bankruptcy. 

Financing Business Strategies

Swiss Talent And Innovation ‘Needs More Financing To Flourish’

Bookmark
  • Interviews
By Ayisha Sharma

With excellent academic centers and a thriving start-up scene, Switzerland’s biotech scene has garnered significant interest in recent years. However, without being a priority for EU funds, the sector remains reliant on foreign cash and needs a funding push from within to boost success.

Financing Switzerland

Oncology’s Hold Over The Pharma Pipeline Increases As Growth Slows

Bookmark
  • Analysis
By Alex Shimmings

The rate of growth of the pharma pipeline slowed last year as oncology and rare diseases tightened their grip on R&D. There are also further signs of China’s rise in importance in the industry.

Companies Clinical Trials
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Adagio Pharmaceuticals Ltd.
    • Altavant Sciences
    • Boston Biomedical, Inc.
    • Boston Biomedical Pharma, Inc.
    • Cannasat Therapeutics Inc.
    • Cynapsus Therapeutics, Inc.
    • Dainippon Sumitomo Pharma Co., Ltd.
    • Dainippon Sumitomo Pharma Europe Ltd.
    • DS Pharma Promo Co., Ltd,
    • Elevation Pharmaceuticals, Inc.
    • Enzyvant Therapeutics, Inc.
    • Enzyvant Sciences, Ltd.
    • Myovant Sciences Ltd
    • Myovant Sciences GmbH
    • Myovant Sciences, Inc.
    • Oryx Pharmaceuticals Inc.
    • SB Bioscience Co., Ltd.
    • Spirovant Sciences
    • Sumitomo Chemical Co., Ltd.
    • Sumitomo Dainippon Pharma America, Inc. (formerly Dainippon Sumitomo Pharma America Holdings, Inc.)
    • Sumitomo Dainippon Pharma Oncology, Inc.
    • Sumitomo Pharmaceuticals America
    • Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.
    • Sumitovant Biopharma
    • Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.)
    • Sunovion Pharmaceuticals Europe Ltd.
    • Sunovion Respiratory Development Inc.
    • Tolero Pharmaceuticals, Inc.
    • Urovant Sciences, Inc.
    • Sumitomo Pharmaceuticals Taiwan Co., Ltd.
    • Sumitomo Dainippon Pharma Co., Ltd.
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By